Alkermes PLC ALKS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
-
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
-
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program
-
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
-
Alkermes plc Reports Second Quarter 2024 Financial Results
-
Alkermes to Report Second Quarter Financial Results on July 24, 2024
Trading Information
- Previous Close Price
- $28.37
- Day Range
- $28.49–29.06
- 52-Week Range
- $22.01–32.88
- Bid/Ask
- $28.97 / $29.23
- Market Cap
- $4.77 Bil
- Volume/Avg
- 1.1 Mil / 1.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- 12.70
- Price/Sales
- 3.27
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 2,100
- Website
- https://www.alkermes.com
Competitors
Valuation
Metric
|
ALKS
|
JNJ
|
---|---|---|
Price/Earnings (Normalized) | 12.70 | 15.29 |
Price/Book Value | 3.74 | 5.39 |
Price/Sales | 3.27 | 4.55 |
Price/Cash Flow | 12.04 | 17.30 |
Price/Earnings
ALKS
JNJ
Financial Strength
Metric
|
ALKS
|
JNJ
|
---|---|---|
Quick Ratio | 2.42 | 0.77 |
Current Ratio | 2.99 | 1.07 |
Interest Coverage | 15.76 | 24.45 |
Quick Ratio
ALKS
JNJ
Profitability
Metric
|
ALKS
|
JNJ
|
---|---|---|
Return on Assets (Normalized) | 17.88% | 13.17% |
Return on Equity (Normalized) | 30.65% | 32.42% |
Return on Invested Capital (Normalized) | 22.85% | 20.93% |
Return on Assets
ALKS
JNJ
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Zoetis Inc Class A
ZTS
| Svrsrnnfst | Dmrw | $86.1 Bil | |||
Merck KGaA ADR
MKKGY
| Yhylyfsnw | Brjwvj | $74.3 Bil | |||
Haleon PLC ADR
HLN
| Lxtbhqbs | Mhtyh | $45.9 Bil | |||
Viatris Inc
VTRS
| Tzyjwfbfs | Vhbv | $13.8 Bil | |||
Dr Reddy's Laboratories Ltd ADR
RDY
| Yvqtyqqx | Jdlb | $13.2 Bil | |||
Catalent Inc
CTLT
| Yjnfctf | Bvzjr | $11.0 Bil | |||
Prestige Consumer Healthcare Inc
PBH
| Rgvdcykc | Wxnnmkb | $3.4 Bil | |||
Perrigo Co PLC
PRGO
| Zzlgjzs | Zvfg | $3.4 Bil | |||
Green Thumb Industries Inc
GTBIF
| Stfpyglc | Vcjdj | $2.4 Bil | |||
Curaleaf Holdings Inc
CURLF
| Vyrwhkfkj | Vkpz | $2.2 Bil |